Abstract
Ancillary molecular testing has emerged as a promising way to refine the preoperative risk stratification of thyroid nodules with indeterminate fine needle aspiration (FNA) biopsy results. Commercially available molecular tests for thyroid FNAs include those that analyze samples for mutations and gene fusions, gene expression alterations, microRNA expression alterations, chromosomal copy number alterations, or a combination thereof. This review summarizes the performance characteristics of the most current iterations of three tests currently marketed for cytologically indeterminate thyroid nodules: ThyroSeq v3, ThyGeNEXT/ThyraMIR, and Afirma Gene Sequencing Classifier.
Keywords:
Thyroid,
Fine needle aspiration,
Molecular diagnostics,
Afirma,
ThyroSeq,
ThyGeNEXT,
ThyraMIR
References
1.
Ali
SZ
, Cibas
ES
. The Bethesda System for Reporting Thyroid Cytopathology: Definitions, Criteria, and Explanatory Notes
. 2nd ed. Cham, Switzerland
: Springer
; 2018
. 2.
Bongiovanni
M
, Spitale
A
, Faquin
WC
, Mazzucchelli
L
, Baloch
ZW
. The Bethesda System for Reporting Thyroid Cytopathology: a meta-analysis
. Acta Cytol
. 2012
;56
(4
):333
–9
.
[PubMed]
0001-55473.
Haugen
BR
, Alexander
EK
, Bible
KC
, Doherty
GM
, Mandel
SJ
, Nikiforov
YE
, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
. Thyroid
. 2016
Jan
;26
(1
):1
–133
.
[PubMed]
1050-72564.
Nikiforov
YE
, Baloch
ZW
, Hodak
SP
, Giordano
TJ
, Lloyd
RV
, Seethala
RR
, et al. Change in Diagnostic Criteria for Noninvasive Follicular Thyroid Neoplasm With Papillarylike Nuclear Features
. JAMA Oncol
. 2018
Aug
;4
(8
):1125
–6
.
[PubMed]
2374-24375.
Nikiforov
YE
, Seethala
RR
, Tallini
G
, Baloch
ZW
, Basolo
F
, Thompson
LD
, et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors
. JAMA Oncol
. 2016
Aug
;2
(8
):1023
–9
.
[PubMed]
2374-24376.
Krane
JF
, Alexander
EK
, Cibas
ES
, Barletta
JA
. Coming to terms with NIFTP: A provisional approach for cytologists
. Cancer Cytopathol
. 2016
Nov
;124
(11
):767
–72
.
[PubMed]
1934-662X7.
Baloch
ZW
, Seethala
RR
, Faquin
WC
, Papotti
MG
, Basolo
F
, Fadda
G
, et al. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): A changing paradigm in thyroid surgical pathology and implications for thyroid cytopathology
. Cancer Cytopathol
. 2016
Sep
;124
(9
):616
–20
.
[PubMed]
1934-662X8.
Sahli
ZT
, Umbricht
CB
, Schneider
EB
, Zeiger
MA
. Thyroid Nodule Diagnostic Markers in the Face of the New NIFTP Category: time for a Reset?
Thyroid
. 2017
Nov
;27
(11
):1393
–9
.
[PubMed]
1050-72569.
Agrawal
N
, Akbani
R
, Aksoy
BA
, Ally
A
, Arachchi
H
, Asa
SL
, et al.; Cancer Genome Atlas Research Network
. Integrated genomic characterization of papillary thyroid carcinoma
. Cell
. 2014
Oct
;159
(3
):676
–90
.
[PubMed]
0092-867410.
Yoo
SK
, Lee
S
, Kim
SJ
, Jee
HG
, Kim
BA
, Cho
H
, et al. Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers
. PLoS Genet
. 2016
Aug
;12
(8
):e1006239
.
[PubMed]
1553-739011.
Kim
TH
, Lee
M
, Kwon
AY
, Choe
JH
, Kim
JH
, Kim
JS
, et al. Molecular genotyping of the non-invasive encapsulated follicular variant of papillary thyroid carcinoma
. Histopathology
. 2018
Mar
;72
(4
):648
–61
.
[PubMed]
0309-016712.
McFadden
DG
, Dias-Santagata
D
, Sadow
PM
, Lynch
KD
, Lubitz
C
, Donovan
SE
, et al. Identification of oncogenic mutations and gene fusions in the follicular variant of papillary thyroid carcinoma
. J Clin Endocrinol Metab
. 2014
Nov
;99
(11
):E2457
–62
.
[PubMed]
0021-972X13.
Landa
I
, Ganly
I
, Chan
TA
, Mitsutake
N
, Matsuse
M
, Ibrahimpasic
T
, et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease
. J Clin Endocrinol Metab
. 2013
Sep
;98
(9
):E1562
–6
.
[PubMed]
0021-972X14.
Sykorova
V
, Dvorakova
S
, Vcelak
J
, Vaclavikova
E
, Halkova
T
, Kodetova
D
, et al. Search for new genetic biomarkers in poorly differentiated and anaplastic thyroid carcinomas using next generation sequencing
. Anticancer Res
. 2015
Apr
;35
(4
):2029
–36
.
[PubMed]
1791-753015.
Kunstman
JW
, Juhlin
CC
, Goh
G
, Brown
TC
, Stenman
A
, Healy
JM
, et al. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing
. Hum Mol Genet
. 2015
Apr
;24
(8
):2318
–29
.
[PubMed]
0964-690616.
Xu
B
, Ghossein
R
. Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma
. Endocr Pathol
. 2016
Sep
;27
(3
):205
–12
.
[PubMed]
1046-397617.
Ganly
I
, Makarov
V
, Deraje
S
, Dong
Y
, Reznik
E
, Seshan
V
, et al. Integrated Genomic Analysis of Hurthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. Cancer Cell. 2018
;34(2):256-70 e5.18.
Gopal
RK
, Kubler
K
, Calvo
SE
, Polak
P
, Livitz
D
, Rosebrock
D
, et al. Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hurthle Cell Carcinoma.
Cancer Cell. 2018
;34(2):242-55 e5. 19.
Corver
WE
, Ruano
D
, Weijers
K
, den Hartog
WC
, van Nieuwenhuizen
MP
, de Miranda
N
, et al. Genome haploidisation with chromosome 7 retention in oncocytic follicular thyroid carcinoma
. PLoS One
. 2012
;7
(6
):e38287
.
[PubMed]
1932-620320.
Nikiforov
YE
, Steward
DL
, Robinson-Smith
TM
, Haugen
BR
, Klopper
JP
, Zhu
Z
, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules
. J Clin Endocrinol Metab
. 2009
Jun
;94
(6
):2092
–8
.
[PubMed]
0021-972X21.
Nikiforov
YE
, Ohori
NP
, Hodak
SP
, Carty
SE
, LeBeau
SO
, Ferris
RL
, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples
. J Clin Endocrinol Metab
. 2011
Nov
;96
(11
):3390
–7
.
[PubMed]
0021-972X22.
Eszlinger
M
, Krogdahl
A
, Münz
S
, Rehfeld
C
, Precht Jensen
EM
, Ferraz
C
, et al. Impact of molecular screening for point mutations and rearrangements in routine air-dried fine-needle aspiration samples of thyroid nodules
. Thyroid
. 2014
Feb
;24
(2
):305
–13
.
[PubMed]
1050-725623.
Eszlinger
M
, Piana
S
, Moll
A
, Bösenberg
E
, Bisagni
A
, Ciarrocchi
A
, et al. Molecular testing of thyroid fine-needle aspirations improves presurgical diagnosis and supports the histologic identification of minimally invasive follicular thyroid carcinomas
. Thyroid
. 2015
Apr
;25
(4
):401
–9
.
[PubMed]
1050-725624.
Labourier
E
, Shifrin
A
, Busseniers
AE
, Lupo
MA
, Manganelli
ML
, Andruss
B
, et al. Molecular Testing for miRNA, mRNA, and DNA on Fine-Needle Aspiration Improves the Preoperative Diagnosis of Thyroid Nodules With Indeterminate Cytology
. J Clin Endocrinol Metab
. 2015
Jul
;100
(7
):2743
–50
.
[PubMed]
0021-972X25.
Nikiforova
MN
, Mercurio
S
, Wald
AI
, Barbi de Moura
M
, Callenberg
K
, Santana-Santos
L
, et al. Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules
. Cancer
. 2018
Apr
;124
(8
):1682
–90
.
[PubMed]
0008-543X26.
Steward
DL
, Carty
SE
, Sippel
RS
, Yang
SP
, Sosa
JA
, Sipos
JA
, et al. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study
. JAMA Oncol
. 2018
Nov
.
[PubMed]
2374-243727.
Marcadis
AR
, Valderrabano
P
, Ho
AS
, Tepe
J
, Swartzwelder
CE
, Byrd
S
, et al. Interinstitutional Variation in Predictive Value of the Thyroseq V2 Genomic Classifier for Cytologically Indeterminate Thyroid Nodules
. Surgery
. 2018
.
[PubMed]
0039-606028.
Sahli
ZT
, Smith
PW
, Umbricht
CB
, Zeiger
MA
. Preoperative Molecular Markers in Thyroid Nodules
. Front Endocrinol (Lausanne)
. 2018
Apr
;9
:179
.
[PubMed]
1664-239229.
Shrestha
RT
, Evasovich
MR
, Amin
K
, Radulescu
A
, Sanghvi
TS
, Nelson
AC
, et al. Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience
. Thyroid
. 2016
Aug
;26
(8
):1068
–76
.
[PubMed]
1050-725630.
Taye
A
, Gurciullo
D
, Miles
BA
, Gupta
A
, Owen
RP
, Inabnet
WB
3rd, et al. Clinical performance of a next-generation sequencing assay (ThyroSeq v2) in the evaluation of indeterminate thyroid nodules
. Surgery
. 2018
Jan
;163
(1
):97
–103
.
[PubMed]
0039-606031.
Valderrabano
P
, Khazai
L
, Leon
ME
, Thompson
ZJ
, Ma
Z
, Chung
CH
, et al. Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology
. Endocr Relat Cancer
. 2017
Mar
;24
(3
):127
–36
.
[PubMed]
1351-008832.
Nikiforov
YE
, Carty
SE
, Chiosea
SI
, Coyne
C
, Duvvuri
U
, Ferris
RL
, et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay
. Cancer
. 2014
Dec
;120
(23
):3627
–34
.
[PubMed]
0008-543X33.
Nikiforov
YE
, Carty
SE
, Chiosea
SI
, Coyne
C
, Duvvuri
U
, Ferris
RL
, et al. Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology
. Thyroid
. 2015
Nov
;25
(11
):1217
–23
.
[PubMed]
1050-725634.
Alexander
EK
, Kennedy
GC
, Baloch
ZW
, Cibas
ES
, Chudova
D
, Diggans
J
, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology
. N Engl J Med
. 2012
Aug
;367
(8
):705
–15
.
[PubMed]
0028-479335.
Alexander
EK
, Schorr
M
, Klopper
J
, Kim
C
, Sipos
J
, Nabhan
F
, et al. Multicenter clinical experience with the Afirma gene expression classifier
. J Clin Endocrinol Metab
. 2014
Jan
;99
(1
):119
–25
.
[PubMed]
0021-972X36.
Harrell
RM
, Bimston
DN
. Surgical utility of Afirma: effects of high cancer prevalence and oncocytic cell types in patients with indeterminate thyroid cytology
. Endocr Pract
. 2014
Apr
;20
(4
):364
–9
.
[PubMed]
1530-891X37.
McIver
B
, Castro
MR
, Morris
JC
, Bernet
V
, Smallridge
R
, Henry
M
, et al. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules
. J Clin Endocrinol Metab
. 2014
Nov
;99
(11
):4069
–77
.
[PubMed]
0021-972X38.
Lastra
RR
, Pramick
MR
, Crammer
CJ
, LiVolsi
VA
, Baloch
ZW
. Implications of a suspicious afirma test result in thyroid fine-needle aspiration cytology: an institutional experience
. Cancer Cytopathol
. 2014
Oct
;122
(10
):737
–44
.
[PubMed]
1934-662X39.
Marti
JL
, Avadhani
V
, Donatelli
LA
, Niyogi
S
, Wang
B
, Wong
RJ
, et al. Wide Inter-institutional Variation in Performance of a Molecular Classifier for Indeterminate Thyroid Nodules
. Ann Surg Oncol
. 2015
Nov
;22
(12
):3996
–4001
.
[PubMed]
1068-926540.
Angell
TE
, Frates
MC
, Medici
M
, Liu
X
, Kwong
N
, Cibas
ES
, et al. Afirma Benign Thyroid Nodules Show Similar Growth to Cytologically Benign Nodules During Follow-Up
. J Clin Endocrinol Metab
. 2015
Nov
;100
(11
):E1477
–83
.
[PubMed]
0021-972X41.
Wu
JX
, Young
S
, Hung
ML
, Li
N
, Yang
SE
, Cheung
DS
, et al. Clinical Factors Influencing the Performance of Gene Expression Classifier Testing in Indeterminate Thyroid Nodules
. Thyroid
. 2016
Jul
;26
(7
):916
–22
.
[PubMed]
1050-725642.
Samulski
TD
, LiVolsi
VA
, Wong
LQ
, Baloch
Z
. Usage trends and performance characteristics of a “gene expression classifier” in the management of thyroid nodules: an institutional experience
. Diagn Cytopathol
. 2016
Nov
;44
(11
):867
–73
.
[PubMed]
8755-103943.
Chaudhary
S
, Hou
Y
, Shen
R
, Hooda
S
, Li
Z
. Impact of the Afirma Gene Expression Classifier Result on the Surgical Management of Thyroid Nodules with Category III/IV Cytology and Its Correlation with Surgical Outcome
. Acta Cytol
. 2016
;60
(3
):205
–10
.
[PubMed]
0001-554744.
Brauner
E
, Holmes
BJ
, Krane
JF
, Nishino
M
, Zurakowski
D
, Hennessey
JV
, et al. Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules
. Thyroid
. 2015
Jul
;25
(7
):789
–96
.
[PubMed]
1050-725645.
Celik
B
, Whetsell
CR
, Nassar
A
. Afirma GEC and thyroid lesions: an institutional experience
. Diagn Cytopathol
. 2015
Dec
;43
(12
):966
–70
.
[PubMed]
8755-103946.
Sacks
WL
, Bose
S
, Zumsteg
ZS
, Wong
R
, Shiao
SL
, Braunstein
GD
, et al. Impact of Afirma gene expression classifier on cytopathology diagnosis and rate of thyroidectomy
. Cancer Cytopathol
. 2016
Oct
;124
(10
):722
–8
.
[PubMed]
1934-662X47.
Villabona
CV
, Mohan
V
, Arce
KM
, Diacovo
J
, Aggarwal
A
, Betancourt
J
, et al. Utility of Ultrasound Versus Gene Expression Classifier in Thyroid Nodules with Atypia of Undetermined Significance
. Endocr Pract
. 2016
Oct
;22
(10
):1199
–203
.
[PubMed]
1530-891X48.
Kloos
RT
, Monroe
RJ
, Traweek
ST
, Lanman
RB
, Kennedy
GC
. A Genomic Alternative to Identify Medullary Thyroid Cancer Preoperatively in Thyroid Nodules with Indeterminate Cytology
. Thyroid
. 2016
Jun
;26
(6
):785
–93
.
[PubMed]
1050-725649.
Pankratz
DG
, Hu
Z
, Kim
SY
, Monroe
RJ
, Wong
MG
, Traweek
ST
, et al. Analytical Performance of a Gene Expression Classifier for Medullary Thyroid Carcinoma
. Thyroid
. 2016
Nov
;26
(11
):1573
–80
.
[PubMed]
1050-725650.
Patel
KN
, Angell
TE
, Babiarz
J
, Barth
NM
, Blevins
T
, Duh
QY
, et al. Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules
. JAMA Surg
. 2018
Sep
;153
(9
):817
–24
.
[PubMed]
2168-625451.
Livhits
MJ
, Kuo
EJ
, Leung
AM
, Rao
J
, Levin
M
, Douek
ML
, et al. Gene Expression Classifier vs Targeted Next-Generation Sequencing in the Management of Indeterminate Thyroid Nodules
. J Clin Endocrinol Metab
. 2018
Jun
;103
(6
):2261
–8
.
[PubMed]
0021-972X52.
Jug
RC
, Datto
MB
, Jiang
XS
. Molecular testing for indeterminate thyroid nodules: performance of the Afirma gene expression classifier and ThyroSeq panel
. Cancer Cytopathol
. 2018
Jul
;126
(7
):471
–80
.
[PubMed]
1934-662X53.
Strickland
KC
, Vivero
M
, Jo
VY
, Lowe
AC
, Hollowell
M
, Qian
X
, et al. Preoperative Cytologic Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: A Prospective Analysis
. Thyroid
. 2016
Oct
;26
(10
):1466
–71
.
[PubMed]
1050-725654.
Howitt
BE
, Chang
S
, Eszlinger
M
, Paschke
R
, Drage
MG
, Krane
JF
, et al. Fine-needle aspiration diagnoses of noninvasive follicular variant of papillary thyroid carcinoma
. Am J Clin Pathol
. 2015
Dec
;144
(6
):850
–7
.
[PubMed]
0002-917355.
Paulson
VA
, Shivdasani
P
, Angell
TE
, Cibas
ES
, Krane
JF
, Lindeman
NI
, et al. Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features Accounts for More Than Half of “Carcinomas” Harboring RAS Mutations
. Thyroid
. 2017
Apr
;27
(4
):506
–11
.
[PubMed]
1050-725656.
Howitt
BE
, Jia
Y
, Sholl
LM
, Barletta
JA
. Molecular alterations in partially-encapsulated or well-circumscribed follicular variant of papillary thyroid carcinoma
. Thyroid
. 2013
Oct
;23
(10
):1256
–62
.
[PubMed]
1050-725657.
Zhao
L
, Dias-Santagata
D
, Sadow
PM
, Faquin
WC
. Cytological, molecular, and clinical features of noninvasive follicular thyroid neoplasm with papillary-like nuclear features versus invasive forms of follicular variant of papillary thyroid carcinoma
. Cancer Cytopathol
. 2017
May
;125
(5
):323
–31
.
[PubMed]
1934-662X58.
Giannini
R
, Ugolini
C
, Poma
AM
, Urpì
M
, Niccoli
C
, Elisei
R
, et al. Identification of Two Distinct Molecular Subtypes of Non-Invasive Follicular Neoplasm with Papillary-Like Nuclear Features by Digital RNA Counting
. Thyroid
. 2017
Oct
;27
(10
):1267
–76
.
[PubMed]
1050-725659.
Brandler
TC
, Liu
CZ
, Cho
M
, Zhou
F
, Cangiarella
J
, Yee-Chang
M
, et al. Does Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features (NIFTP) Have a Unique Molecular Profile?
Am J Clin Pathol
. 2018
Oct
;150
(5
):451
–60
.
[PubMed]
0002-917360.
Valderrabano
P
, Khazai
L
, Thompson
ZJ
, Leon
ME
, Otto
KJ
, Hallanger-Johnson
JE
, et al. Impact of oncogene panel results on surgical management of cytologically indeterminate thyroid nodules
. Head Neck
. 2018
Aug
;40
(8
):1812
–23
.
[PubMed]
1043-307461.
Hang
JF
, Westra
WH
, Cooper
DS
, Ali
SZ
. The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on the performance of the Afirma gene expression classifier
. Cancer Cytopathol
. 2017
Sep
;125
(9
):683
–91
.
[PubMed]
1934-662X62.
Brandler
TC
, Zhou
F
, Liu
CZ
, Cho
M
, Lau
RP
, Simsir
A
, et al. Can noninvasive follicular thyroid neoplasm with papillary-like nuclear features be distinguished from classic papillary thyroid carcinoma and follicular adenomas by fine-needle aspiration?
Cancer Cytopathol
. 2017
Jun
;125
(6
):378
–88
.
[PubMed]
1934-662X63.
Song
YS
, Lim
JA
, Choi
H
, Won
JK
, Moon
JH
, Cho
SW
, et al. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients
. Cancer
. 2016
May
;122
(9
):1370
–9
.
[PubMed]
0008-543X64.
Baca
SC
, Wong
KS
, Strickland
KC
, Heller
HT
, Kim
MI
, Barletta
JA
, et al. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes
. Cancer Cytopathol
. 2017
May
;125
(5
):313
–22
.
[PubMed]
1934-662X65.
Wong
KS
, Angell
TE
, Strickland
KC
, Alexander
EK
, Cibas
ES
, Krane
JF
, et al. Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier
. Thyroid
. 2016
Jul
;26
(7
):911
–5
.
[PubMed]
1050-7256© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
